Roche, Fluidigm Ink Deal to Co-market Access Array Platform with 454 Sequencing | GenomeWeb

By Justin Petrone

Fluidigm and Roche 454 Life Sciences this week announced that they have entered a worldwide co-promotional agreement that pairs Fluidigm's amplicon sample-preparation platform with Roche 454's high-throughput sequencers.

The partners will market Fluidigm’s Access Array System for use in target enrichment prior to sequencing on Roche 454's GS Junior or GS FLX System.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.